Results 121 to 130 of about 377 (154)
Some of the next articles are maybe not open access.

0573 Application of AASM Clinical Significance Thresholds to Once-Nightly Sodium Oxybate for Improvement in Narcolepsy Symptoms

SLEEP, 2023
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; FT218), an investigational, extended-release treatment, was evaluated for the treatment of narcolepsy in adults in the phase 3 REST-ON clinical trial (NCT02720744).
Thomas Roth   +6 more
openaire   +1 more source

0638 Stability of Once-Nightly Sodium Oxybate in Alternative Liquid Reconstitution Vehicles

SLEEP
Abstract Introduction LUMRYZ™ is a once-nightly formulation of sodium oxybate (ON-SXB) containing both immediate and pH-dependent controlled-release granules designed to be reconstituted in water and administered orally.
Maggie Lavender   +6 more
openaire   +1 more source

0607 Improvement in Sleep Latency With FT218 (Once-Nightly Sodium Oxybate): Analysis From the Phase 3 REST-ON Clinical Trial

SLEEP, 2023
Abstract Introduction In the phase 3 REST-ON trial (NCT02720744), mean sleep latency on the Maintenance of Wakefulness Test (MWT) was significantly improved vs placebo with investigational, extended-release once-nightly sodium oxybate (FT218 [ON-SXB]; P< 0.001).
Michael Thorpy   +5 more
openaire   +1 more source

0636 Assessing Usability of Once-Nightly Sodium Oxybate Extended-Release Oral Suspension for Narcolepsy

SLEEP
Abstract Introduction Sodium oxybate, available in once-nightly and twice-nightly formulations, is indicated for treatment of cataplexy or excessive daytime sleepiness in narcolepsy. Once-nightly sodium oxybate extended-release oral suspension (ON-SXB; LUMRYZ™) may alleviate potential dosing ...
Maggie Lavender   +5 more
openaire   +1 more source

0855 Successful Transition from Twice-Nightly Oxybates to Once-Nightly Sodium Oxybate: A Post Hoc Analysis from RESTORE

SLEEP
Abstract Introduction Extended-release, once-nightly sodium oxybate (ON-SXB; LUMRYZ™) eliminates the middle-of-the-night dosing required with immediate-release, twice-nightly oxybates (TN-OXBs). RESTORE (NCT04451668) was an open label/switch study that assessed the safety and tolerability of ON-SXB in
Adrian Santamaria   +7 more
openaire   +1 more source

0628 Consistent Efficacy of Once-Nightly Sodium Oxybate Across Patient Demographic and Baseline Disease Characteristics

SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) or 2 (NT2) in the phase 3 REST-ON trial; treatment with 6, 7.5, and 9 g demonstrated significant improvements vs placebo (all P< 0.001) for the coprimary endpoints of ...
Michael Thorpy   +7 more
openaire   +1 more source

Long-Term Safety of Once-Nightly Sodium Oxybate: Interim Data From RESTORE

Sleep Medicine, 2022
T. Stern   +8 more
openaire   +1 more source

0835 Improvement of Individual Excessive Daytime Sleepiness Symptoms with Once-Nightly Sodium Oxybate for Narcolepsy

SLEEP
Abstract Introduction The Epworth Sleepiness Scale (ESS) is a commonly used 8-item patient-reported outcome measure for excessive daytime sleepiness. While aggregate data are typically presented, individual domains vary in clinical significance.
Heidy Merius   +5 more
openaire   +1 more source

DOSE TITRATION AND TOLERABILITY OF ONCE-NIGHTLY SODIUM OXYBATE: INTERIM DATA FROM RESTORE

Chest, 2022
ASIM ROY   +5 more
openaire   +1 more source

0637 Composite Response with Once-Nightly Sodium Oxybate: Symptom Improvement in Participants with Narcolepsy Type 1

SLEEP
Abstract Introduction A novel once-nightly formulation of sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) and 2 (NT2) in the phase 3 REST-ON trial (NCT02720744).
Luis Ortiz   +7 more
openaire   +1 more source

Home - About - Disclaimer - Privacy